Efficacy and safety of zanamivir in patients with influenza - Impact of age, severity of infections and specific risk factors

Medical Microbiology and Immunology

Volumn 191, Issue 3-4, 2002, Pages 169-173

  Höffken, Gert ^a   Gillissen, Adrian ^b  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b Robert Koch Klinik   (Germany)

Author keywords

Chronic obstructive pulmonary disease; Influenza; Neuraminidase inhibitors; Treatment; Zanamivir

Indexed keywords

LACTOSE; OSELTAMIVIR; SIALIDASE INHIBITOR; ZANAMIVIR;

AGE; ASTHMA; BRONCHITIS; CHRONIC LUNG DISEASE; CLINICAL TRIAL; COUGHING; DEATH; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; EAR INFECTION; HIGH RISK POPULATION; HOSPITALIZATION; HUMAN; INFLUENZA; INFLUENZA VIRUS; LUNG COMPLICATION; LUNG FUNCTION; METHODOLOGY; MORBIDITY; MORTALITY; NAUSEA; NOSE INFECTION; PHARYNGITIS; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SEASONAL VARIATION; SINUSITIS; STATISTICAL SIGNIFICANCE; SYMPTOM; VERTIGO; WINTER;

ADMINISTRATION, ORAL; AGE FACTORS; ANTIVIRAL AGENTS; BACTERIAL INFECTIONS; CHRONIC DISEASE; DOUBLE-BLIND METHOD; GUANIDINES; HUMANS; INFLUENZA A VIRUS; INFLUENZA B VIRUS; INFLUENZA, HUMAN; LUNG DISEASES; PYRANS; RISK FACTORS; SIALIC ACIDS; TIME FACTORS; TREATMENT OUTCOME; ZANAMIVIR;

EID: 0036454042     PISSN: 03008584     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00430-002-0140-3     Document Type: Review

References (19)

1. Centers for Disease Control and Prevention (1999) Neuraminidase inhibitors for treatment of influenza A and B infections. MMWR Morb Mortal Wkly Rep 48:1-10
2. Centers for Diseases Control and Prevention (2000) Prevention and Control of influenza: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 49:1-38
3. Centers for Diseases Control and Prevention (2001) Prevention and Control of influenza: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 50:1-44
4. Dines GD, Bethell R, Daniel M (1998) Preclinical development of low toxicity drugs. Focus on Zanamivir, an anti-influenza drug. Drug Safety 19:233-241
5. Fleming DM, Moult AB, Keene O (2000) Indicators and significance of severity in influenza patients. Proceedings of the Meeting on Options for the Control of Influenza IV, Crete, Greece. Abstr. no. W 22-8
6. Glaxo Wellcome Inc. (2000) Relenza® (Zanamivir for Inhalation) (Package Insert). Glaxo Wellcome, Triangle Park
7. Glezen WP, Decker M, Perrotta DM (1987) Survey of underlying conditions of persons hospitalized with acute respiatory disease during influenza epidemics in Houston, 1978-1981. Am Rev Respir Dis 36:50-55
8. Hayden FG, Osterhaus AD, Treanor JJ, Fleming DM, Aoki FY, Nicholson KG, Bohnen AM, Hirst HM, Keene O, Wightman K (1997) Efficacy and safety of the neuraminidease inhibitor zanamivir in the treatment of influenzavirus infections. N Engl J Med 337:874-880
9. Jefferson T, Demicheli V, Deeks J, Rivetti D (2001) Neuraminidase inhibitors for preventing and treating influenza in healthy adults (Cochrane Review). Update Software, Issue 1. The Cochrane Library, Oxford
10. Liu C, Air GM (1993) Selection and characterization of a neuraminidase-minus mutant of influenza virus and ist rescue by cloned neuraminidase genes. Virology 194:43-47
11. Mäkelä MJ, Pauksen K, Rostila T, Fleming DM, Man CY, Keene ON, Webster A (2000) Clinical efficacy and safety of the orally inhaled neuraminidase inhibitor zanamivir in the treatment of influenza: A randomized double-blind, placebo-controlled European study. J Infect 40:42-48
12. Murphy KR, Eivindson A, Pauksen K, Stein WJ, Tellier G, Watts R, Léophonte P, Sharp SJ, Loeschel E (2000) Efficacy and safety of inhaled zanamivir for the treatment of influenza in patients with asthma or chronic obstructive pulmonary disease. Clin Drug Invest 5:337-349
13. Nicholson KG, Kent J, Ireland DC (1993) Respiratory viruses and exacerbations of asthma in adults. Br Med J 307: 982-986
14. Roldaan AC, Masural N (1982) Viral respiratory infections in asthmatic children staying in a mountain resort. Eur J Respir Dis 63:140-150
15. Teichtahl H, Buckmaster N, Pertnikovs E (1997) The incidence of respiratory tract infection in adults requiring hospitalisation for asthma. Chest 112:591-596
16. The MIST Study Group (1998) Randomized trial of efficacy and safety of inhaled zanamivir in treatment of influenza A and B virus infections. Lancet 352:1877-1881
17. Vogel G, Lange W (eds) (2000) Influenza - Neue Diagnostische und Therapeutische Chancen. Thieme, Stuttgart
18. Waghorn SL, Goa KL (1998) Zanamivir. Drugs 55:721-725
19. Wiselka MJ, Kent J, Nicholson KG, Stern M (1992) Influenza and asthma. Lancet 339:367-368